These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
687 related articles for article (PubMed ID: 25320537)
1. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer. Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537 [TBL] [Abstract][Full Text] [Related]
2. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560 [TBL] [Abstract][Full Text] [Related]
3. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer. Nakachi K; Furuse J; Kinoshita T; Kawashima M; Ishii H; Ikeda M; Mitsunaga S; Shimizu S Cancer Chemother Pharmacol; 2010 Aug; 66(3):527-34. PubMed ID: 19967537 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040 [TBL] [Abstract][Full Text] [Related]
5. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Hunter KU; Feng FY; Griffith KA; Francis IR; Lawrence TS; Desai S; Murphy JD; Zalupski MM; Ben-Josef E Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):921-6. PubMed ID: 22208966 [TBL] [Abstract][Full Text] [Related]
6. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286 [TBL] [Abstract][Full Text] [Related]
7. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer. Chang JS; Wang ML; Koom WS; Yoon HI; Chung Y; Song SY; Seong J Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1448-54. PubMed ID: 22285669 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Hara T; Denda T; Tawada K; Imagumbai T; Araki H; Sakai M; Hatano K; Kawakami H; Uno T; Ito H; Yokosuka O Int J Radiat Oncol Biol Phys; 2011 May; 80(1):119-25. PubMed ID: 20605363 [TBL] [Abstract][Full Text] [Related]
9. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027 [TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367 [TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study. Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250 [TBL] [Abstract][Full Text] [Related]
12. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367 [TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Goji T; Kimura T; Miyamoto H; Takehara M; Kagemoto K; Okada Y; Okazaki J; Takaoka Y; Miyamoto Y; Mitsui Y; Matsumoto S; Sueuchi T; Tanaka K; Fujino Y; Takaoka T; Kitamura S; Okamoto K; Kimura M; Sogabe M; Muguruma N; Okahisa T; Sato Y; Sagawa T; Fujikawa K; Sato Y; Ikushima H; Takayama T Cancer Chemother Pharmacol; 2015 Sep; 76(3):615-20. PubMed ID: 26220846 [TBL] [Abstract][Full Text] [Related]
14. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S; Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002 [TBL] [Abstract][Full Text] [Related]
16. A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer. Eguchi H; Nagano H; Kobayashi S; Kawamoto K; Wada H; Hama N; Tomimaru Y; Akita H; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y Cancer Chemother Pharmacol; 2014 Feb; 73(2):309-15. PubMed ID: 24258457 [TBL] [Abstract][Full Text] [Related]
17. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K Oncology; 2005; 69(5):421-7. PubMed ID: 16319514 [TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363 [TBL] [Abstract][Full Text] [Related]
19. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study. Woo SM; Kim MK; Joo J; Yoon KA; Park B; Park SJ; Han SS; Lee JH; Hong EK; Kim YH; Moon H; Kong SY; Kim TH; Lee WJ Cancer Res Treat; 2017 Oct; 49(4):1022-1032. PubMed ID: 28111423 [TBL] [Abstract][Full Text] [Related]
20. A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer. Kobayashi S; Honda G; Kurata M; Okuda Y; Sakamoto K; Karasawa K; Chang T; Egawa N; Kamisawa T; Omuro Y; Tsuruta K Hepatogastroenterology; 2015 Jun; 62(140):1031-6. PubMed ID: 26902051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]